Experts Video Reports: Neuroendocrine Tumours track

Learn about key results illustrated by slides from the sessions!

The Neuroendocrine Tumours track 2019 is supported with an unrestricted grant from IPSEN . The selection of study results covered in this track is exclusively under the responsibility of ESMO and the speakers selected by ESMO.

Expert video Report on Neuroendocrine Tumours

Speaker: Philippe Ruszniewski

Reporting from ESMO Congress 2019, Philippe Ruszniewski comments on results of 3 studies that evaluated the effects of the addition of radioembolisation to peptide receptor radionuclide therapy in patients with advanced neuroendocrine tumours (NETs), doubling a dose of lanreotide in patients with pancreatic or midgut NETs who progressed on conventional dosage, and the efficacy and safety of novel tyrosine kinase inhibitor surufatinib in well-differentiated advanced extrapancreatic NETs.

Expert video report on Neuroendocrine neoplasms: From biology to treatment novelties

Speaker: Nicola Fazio

Nicola Fazio provides an overview of the current state of the art regarding the management of neuroendocrine neoplasms by reviewing tumour biology and recent novelties in diagnostic imaging methods, and concluding with the adoption of treatment novelties into clinical practice.

Reprinted by permission from Springer Nature: Nature, Whole-genome landscape of pancreatic neuroendocrine tumours, Aldo Scarpa, David K. Chang, Katia Nones, Vincenzo Corbo, Ann-Marie Patch et al., 543(7643), Copyright (2017)

Expert video report on clinical management of gastroenteropancreatic neuroendocrine neoplasms

Speaker: Chris Verslype

Chris Verslype explains that the management of gastroenteropancreatic neuroendocrine neoplasms (GEP NENs) should rely on pathology findings on how well differentiated the tumour is, and the level of proliferation marker Ki67. He describes treatment options and follow-up plan recommendations according to disease staging.

Expert video report on Carcinoid Syndrome

Speaker: Juan Valle

Juan Valle explains that some patients with neuroendocrine tumours suffer from carcinoid syndrome characterised by very specific symptoms. He stressed out why it is important to detect it, and details its physiopathology, how carcinoid syndrome should be managed and what are the available treatments.

Reprinted from:
Mamikunian G, et al, Neuroendocrine Tumors: A Comprehensive Guide to Diagnosis and Management. (4th ed.) Inglewood, CA: Inter Science Institute; 2009, with permission from InterScience Institute.
Daniel M Halperin et al., Lancet Oncol., Vol. 18(4), Frequency of carcinoid syndrome at neuroendocrine tumour diagnosis: a population-based study, Pages 525-534, Copyright (2017), with permission from Elsevier.
Pavel M, et al., Neuroendocrinology, Vol. 103(2), ENETS Consensus Guidelines Update for the Management of Distant Metastatic Disease of Intestinal, Pancreatic, Bronchial Neuroendocrine Neoplasms (NEN) and NEN of Unknown Primary Site, Pages 172-85, Copyright (2016), with permission from Karger.
Jensen R. In: Harrison’s Principles of Internal Medicine Online. (17th ed) New York, NY: McGraw-Hill, Inc; Copyright (2008), with permission from McGraw-Hill Education.

 

More ESMO videos on Endocrine and Neuroendocrine Cancers from the ESMO Channel

View the full playlist on the ESMO Channel

ESMO thanks the sponsor for supporting this track in 2019: